XenoTherapeutics to Acquire ESSA Pharma at $1.91/Share Amid 60% Stock Plunge

Introduction

ESSA Pharma Inc (NASDAQ: EPIX; Korean: ESSA 파머) is a clinical-stage biotechnology company developing therapies for prostate cancer. The firm’s lead candidate, masofaniten (formerly EPI-7386), targets the N-terminal domain of the androgen receptor, providing a mechanism to disrupt androgen signaling in prostate tumors.

Corporate Structure and Leadership

ESSA Pharma employs between 11 and 50 professionals across research, clinical development, and corporate functions.
• David Parkinson, M.D., has served as President and Chief Executive Officer since 2016 and has over 30 years of experience in oncology drug development, including previous roles at Biogen, Amgen, and Novartis.
• Robert Wood, CPA, CMA, joined as Chief Financial Officer in 2013 and has more than 30 years of finance and management experience in biopharma and early-stage companies.
• Harvey Glickman, Ph.D., has been the founding Chairman since 2010 and has a background in healthcare entrepreneurship, including receiving the Ernst & Young Entrepreneur of the Year Award in 2004.

Prostate cancer by National Cancer Institute

Recent Developments and News

On July 14, 2025, ESSA Pharma announced a definitive agreement to be acquired by XenoTherapeutics, Inc., a biotechnology company, with financing provided by XOMA Royalty Corporation. Under the terms of the transaction, shareholders are estimated to receive approximately US$1.91 per share in cash, plus one contingent value right (CVR) per share, entitling holders to up to US$0.06 in additional payments within 18 months following the closing of the transaction. The arrangement is to be executed via a court-approved plan of arrangement under British Columbia law and requires shareholder and court approvals. The transaction is expected to close in the second half of 2025.

On August 13, 2025, ESSA filed its Form 10-Q for the quarter ended June 30, 2025. On August 14, 2025, the company submitted a DEFA14A proxy statement and an 8-K current report, both related to the special meeting for voting on the transaction.

Financial and Strategic Analysis

As of August 25, 2025, ESSA Pharma’s share price was US$0.7589, reflecting a 60.68% decline over the preceding period, with a trading volume of 34,520,104 shares. According to Yahoo Finance (as of August 22, 2025):
• Market Capitalization: US$91.31 million
• Enterprise Value: –US$18.31 million
• Price/Book Ratio: 0.84
• Beta (5Y Monthly): 1.56
• Trailing EPS (TTM): –US$0.57
• Net Loss (TTM): –US$25.27 million
• Total Cash (MRQ): US$109.62 million
• Levered Free Cash Flow (TTM): –US$14.56 million

The company’s cash position supports the completion of ongoing clinical trials, and the net losses are consistent with the typical investment profile of a clinical-stage biotech. The planned acquisition by XenoTherapeutics facilitates value realization for shareholders and addresses ESSA’s funding requirements through a transition to a non-profit structure.

Market Position and Industry Context

Prostate cancer is a significant cause of cancer mortality in men, and the development of resistance to existing antiandrogen therapies presents ongoing challenges. ESSA Pharma’s research focuses on targeting the N-terminal domain of the androgen receptor, addressing mechanisms not covered by conventional ligand-binding domain inhibitors. Masofaniten is undergoing evaluation as both a monotherapy and in combination with standard antiandrogens in Phase 1/2 trials. Collaborations with Astellas, Bayer, and Janssen support the combination trial protocols, positioning ESSA in a cooperative strategy focused on mitigating drug resistance in androgen receptor-driven prostate cancer.

tl;dr

ESSA Pharma has agreed to be acquired by XenoTherapeutics with backing from XOMA Royalty, offering shareholders approximately US$1.91 per share plus up to US$0.06 per CVR. Shareholder and court approvals are pending, with closing anticipated in the second half of 2025. As of August 25, 2025, the stock trades at US$0.7589, and the company holds US$109.6 million in cash, aiding in the continuation of its prostate cancer clinical programs.